A shipping pallet of vaccines with Novavax's logo on it
FDA Authorizes Novavax COVID-19 Vaccine
Agency members express hope that the availability of a traditional, protein-based vaccine might convince holdouts to get vaccinated.
FDA Authorizes Novavax COVID-19 Vaccine
FDA Authorizes Novavax COVID-19 Vaccine

Agency members express hope that the availability of a traditional, protein-based vaccine might convince holdouts to get vaccinated.

Agency members express hope that the availability of a traditional, protein-based vaccine might convince holdouts to get vaccinated.

spike protein
Group of cells stained in either blue or green in a black background.
Diabetes Marker Linked to COVID-19 Severity in Mice
Alejandra Manjarrez | May 16, 2022
A sugar that’s less abundant in the blood of people with diabetes binds to SARS-CoV-2’s spike protein and disrupts the virus’s ability to fuse with cells.  
Isolated Realistic Coronavirus Covid-19 Molecule in a Biological Environment stock photo
Tweak to N Protein Makes Delta Variant More Infectious
Chloe Tenn | Nov 5, 2021
Using a novel lab technique, researchers identified a mutation that allows the virus to insert more genetic material into host cells.
Characterizing SARS-CoV-2 Antibody Responses in COVID-19 Patients
Characterizing SARS-CoV-2 Antibody Responses in COVID-19 Patients
The Scientist Creative Services Team and Bio-Techne
In this webinar, Javier Castillo-Olivares and Matteo Ferrari will discuss what they have learned about COVID-19 through testing patient sera with automated immunoblotting.
tube of blood labeled positive for COVID-19 Mu variant
What We Know About Mu, the WHO’s Latest Variant of Interest
Christie Wilcox | Sep 7, 2021
The SARS-CoV-2 variant was first detected in January, but its rising prevalence and potential resistance to vaccines has garnered it special attention from the World Health Organization.
an illustration of the sars-cov-2 spike protein in purple tethered to the viral membrane in dark gray
Spike Protein Deletions Linked to COVID-19 Surges: Preprint
Alejandra Manjarrez | Jun 15, 2021
Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.
Learn About Sero-Surveillance During the COVID-19 Pandemic
Using Sero-Surveillance to Combat the COVID-19 Pandemic
The Scientist Creative Services Team and Bio-Rad Laboratories
Immunoassays for detecting, tracking, and testing SARS-CoV-2 antibody responses
regeneron monoclonal antibody sars-cov-2 covid-19 pandemic coronavirus neutralization b.1.351 variant south africa REGN10987 casirivimab and REGN10933 imdevimab
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
First US Case of UK SARS-CoV-2 Variant Detected
Max Kozlov | Dec 30, 2020
Variant B.1.1.7, though likely more contagious than other strains, does not appear to be more deadly.
40679-ts-labtools-antibody-webinar-banner-jp800x560
Probing Antibody Binding to the SARS-CoV-2 Spike Protein
The Scientist Creative Services Team in collaboration with Refeyn
Victor Yin will discuss two single-particle mass analysis methods that shed light on heterogenous, multimeric proteins and their interactions.
UPDATED DEC 21
New SARS-CoV-2 Variant Spreading Rapidly in UK
Max Kozlov | Dec 16, 2020
The significance of the variant remains unclear, but experts remain confident that it will not evade the protection offered by a COVID-19 vaccine.
mrna vaccine covid-19 astrazeneca pfizer biontech moderna coronavirus pandemic sars-cov-2 spike protein
The Promise of mRNA Vaccines
Diana Kwon | Nov 25, 2020
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
SARS-CoV-2 Antibody Durability
The Scientist Creative Services Team
Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Ashley Yeager | Nov 23, 2020
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
furin spike protein sars-cov-2 covid-19 coronavirus pandemic
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
adenovirus vector vaccine covid-19 pandemic coronavirus sars-cov-2 spike protein
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
lowland gorilla ace2 spike protein coronavirus sars-cov-2 binding covid-19 pandemic
Modeling Study Flags Species Susceptible to SARS-CoV-2
Anthony King | Aug 26, 2020
Some critically endangered animals are on the list.
antibody sars-cov-2 spike protein nucleocapsid covid-19 coronavirus pandemic survivors immunology immunity
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
monoclonal antibody antibodies sars-cov-2 covid-19 coronavirus pandemic eli lilly receptor binding domain spike protein
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
ade antibody-dependent enhancement ADE sars-cov-2 coronavorus pandemic covid-19 vaccine
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
Katarina Zimmer | May 26, 2020
There is no evidence that any of the coronavirus vaccines in development worsen a coronavirus infection rather than confer immunity to it, but the phenomenon is something scientists are closely monitoring.